Fakhri B, et al. - Given the association of carfilzomib treatment with improvement in survival in patients with recurrent myeloma in clinical trials with strict eligibility criteria, researchers sought for the actual frequency of cardiac adverse events (CAEs) and pulmonary adverse events (PAEs) and the risk factors associated with these AEs in the myeloma cases from the Surveillance, Epidemiology, and End Results (SEER)–Medicare linked database. They analyzed 635 patients [median age: 72 years (range, 36-94 years); 55% male and 79% white]. Carfilzomib treatment was provided for the median duration of 58 days (range, 1-716 days). New cardiac and pulmonary diagnoses were common among these patients. CAEs more frequently developed among patients with preexisting COPD. CAEs encountered were hypertension, peripheral edema, and heart failure. PAEs encountered were dyspnea, cough, and pneumonia.